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Background
Early institution of therapy has been advocated worldwide.
However, until recently, NACO guidelines recommended
therapy in HIV positive patients with CD4 count <250/µL.
In this study we observed the clinical and immunological
disease progression for a year in treatment naïve patients
with CD4 count between 250-500/µL.
Method
150 treatment naïve adults PLHIV with CD4 count
between 250 -500/mm3 in WHO clinical stage 1 or 2
were included in the study and enrolled into 2 groups at
2:1 ratio and followed for 1 year. Group A with CD4
count between 250-350/mm3 & Group B with CD4
count between 350-500/mm3. At the end of study each
group was evaluated for number of opportunistic infec-
tion, ART conversion, conversion to stage III and IV, lost
to follow up (LFU) and death. Statistical analysis was
done by SPSS 16.0 version. Data were expressed as mean
(±SD) for continuous variable and percentage for catego-
rical variable. An independent sample t-test was used to
detect differences in clinical and laboratory results.
Result
As compared to Group B, Group A had significantly
higher number of opportunistic infection (27% vs 8%,
p=0.006), ART conversion (30% vs 10%, p=0.012), death
(9% vs 0%, p=0.021) and LFU (20% vs 6% p=0.037).
Conclusion
This study reinforces the need of early initiation of
treatment in patients with CD4 <350/ µL.
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